HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, will be attending and presenting at two upcoming investor conference: the Dawson James Small Cap Growth Conference and The ThinkEquity Conference. Slated for Oct. 12, 2022, the Dawson James event will be held in Jupiter, Florida. HeartBeam founder and CEO Branislav Vajdic, PhD, will be joined by chief financial officer Rick Brounstein and chief business officer Jon Hunt, PhD, at the conference to deliver the company’s presentation and also meet one-on-one with meeting attendees. The presentation is scheduled for 10 a.m. ET; it can be viewed live or replayed after the event on the HeartBeam investor relations website. Vajdic, Brounstein and Hunt will also participate in the ThinkEquity event, which will be held in New York City on Oct. 26, 2022. The company managers will deliver a presentation at 4:30 p.m. ET and will also be available to meet one-on-one with those in attendance. The ThinkEquity presentation can also be viewed live.
To view the full press release, visit https://ibn.fm/gEOAn
About HeartBeam Inc.
HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to determine quickly and easily if symptoms are due to a heart attack so care can be expedited if required. HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart-attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the US Food and Drug Administration (“FDA”) for marketing in the United States or other geographies. For more information, visit www.HeartBeam.com.
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork